This inventor holds 1 USPTO granted patent. Top assignee: Meiji Seika Kaisha, Ltd.. Active years: 1979.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1979
Title: Innovations in Antibiotics: The Work of Kunikazu Totsukawa
Introduction
Kunikazu Totsukawa, situated in Ohizumi, Japan, has made significant contributions in the field of antibiotics with his innovative work on the SF-1771 substance. With a total of one patent credited to his name, Totsukawa's research holds great promise in combating bacterial infections.
Latest Patents
The patent details the production of a new antibiotic compound, designated as SF-1771. This novel antibiotic is derived from cultivating a unique strain, Streptomyces toyocaensis SF-1771, in a liquid culture medium under aerobic conditions. The process involves isolating the antibiotic from the fermentation broth by treating it with a synthetic adsorbent resin, followed by chromatographic purification. SF-1771 exhibits antibacterial efficacy against various pathogens, including Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, Staphylococcus aureus, and Bacillus subtilis. Furthermore, Totsukawa's innovation led to the creation of SF-1771-B, a derivative with reduced toxicity while maintaining high antibacterial activity achieved by removing the copper component.
Career Highlights
Totsukawa is associated with Meiji Seika Kaisha, Ltd., where he has been at the forefront of research and development in the area of antibiotics. His pioneering work reflects a commitment to creating more effective treatment options for bacterial infections, which is essential in the ongoing battle against antibiotic resistance.
Collaborations
Throughout his career, Totsukawa has collaborated with esteemed colleagues such as Kazunori Ohba and Takashi Shomura. These partnerships have facilitated the advancement of his research initiatives, contributing to the refinement and development of innovative antibiotic solutions.
Conclusion
Kunikazu Totsukawa's dedication to antibiotic research highlights the importance of innovation in medical science. His patent on the SF-1771 antibiotic demonstrates a significant step forward in addressing bacterial infections, reflecting a blend of scientific expertise and innovative thinking. As the field of antibiotics continues to evolve, Totsukawa's contributions will undoubtedly impact future medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile